Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyHighlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

The recent 2022 ASCO GU Cancers Symposium provided important new data for the management of advanced prostate cancer. Presentations covered in this review of symposia highlights include androgen receptor (AR) inhibitors in patients with metastatic hormone-sensitive prostate cancer, combinations of PARP inhibitors with abiraterone acetate in metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 in metastatic CRPC, some novel therapies, and even a look at an artificial intelligence pathology predictive biomarker.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form